Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3

一种人参皂苷、格列卫耐的技术，应用在含有效成分的医用配制品、碳水化合物有效成分、药物组合等方向，能够解决格列卫耐药性白血病治疗效果差、需要长期给药等问题

Inactive Publication Date: 2017-08-18
INTELLIGENT SYNTHETIC BIOLOGY CENT
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These pharmaceutical compositions have the advantages of being substantially derived from natural products, minimizing side effects, and exhibiting the effect of treating Gleevec-resistant leukemia. Disadvantages of being poor and requiring long-term administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
  • Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
  • Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Discovery of ginsenosides that enhance the cytotoxic activity of NK cells

[0054] In order to discover ginsenosides that affect the cytotoxic activity of NK cells, 15 kinds (C-K, F2, PPD, Rb1, Rb2, Rc, Rd, Rg3, Rh2, F1, PPT, Re, Rg1, Rg2 and Rh1) were used PBMC (peripheral blood mononuclear cell, peripheral blood mononuclear cell) were treated with ginsenoside, and the level of CD107a, which is a marker protein exhibiting a cell-killing effect expressed by NK cells, was measured by flow cytometry ( figure 1 ).

[0055] At this time, the PBMCs screened in the following manner were used. That is, the extracted blood was put into a mononuclear cell preparation tube (Vacutainer Cell Preparation Tube) (sodium heparin (sodium heparin); BD Biosciences (BD biotechnology)), and centrifuged to recover buffy coat (buffy coat). ; lymphocytes and monocyte band (lymphocyte and monocyte band)), and after washing the recovered buffy coat with PBS (phosphate buffered sa...

Embodiment 2

[0058] Example 2: Screen out the ginsenosides that improve the expression of the immune activity factor (IFN-γ) of NK cells

[0059] Treat with the seven ginsenosides discovered in Example 1 above, and screen out the ginsenosides that increase the expression level of the immune activity factor (IFN-γ) of NK cells ( figure 2 ). At this time, the expression level of IFN-γ was determined in the following manner. That is, the PBMCs isolated from the above-mentioned Example 1 were treated with the respective ginsenosides, and the target cells (KCL-22 cell variants) with the same number of cells were treated to stimulate, and then treated with brefeldin A (Brefeldin A) (GolgiPlug; BD Biosciences) for processing. Next, NK cells derived from PBMC were isolated by performing flow cytometric analysis using anti-CD3 antibody and anti-CD56 antibody, and the isolated NK cells were treated with Cytofix / Cytoperm (BD Biosicences) to perforate, and then Anti-IFN-γ antibody was immunostai...

Embodiment 3

[0061] Example 3: Screening out ginsenosides that increase the level of CD107a in non-activated NK cells

[0062] From the four ginsenosides (Rg3, Rh2, F1 and Rg1) screened in Example 2 above, a ginsenoside that induces an increase in the level of CD107a in non-activated NK cells was screened.

[0063] Specifically, after treating NK cells isolated from PBMCs with the four ginsenosides to activate the NK cells, and adding a variant of KCL-22 cells as Gleevec-resistant leukemia cells, CD107a was measured and compared s level( image 3 ). At this time, as a control group, NK cells treated with DMSO (dimethyl sulfoxide) instead of ginsenoside were used.

[0064] image 3 It is a graph showing the effect of ginsenosides on increasing the expression level of CD107a by reacting a variant of KCL-22 cells, which are Gleevec-resistant leukemia cells, with NK cells. Such as image 3 As shown, it was confirmed that the level of CD107a was significantly increased when the KCL-22 ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to: a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or treatment effect on Gleevec-resistant leukemia; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or alleviating Gleevec-resistant leukemia. When using the pharmaceutical composition of the present invention, leukemia exhibiting resistance due to conventional Gleevec can be effectively treated, and thus the pharmaceutical composition can be widely used for effective leukemia treatment.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia comprising ginsenoside F1 or Rg3 as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition comprising Gleevec-resistant A pharmaceutical composition for preventing or treating Gleevec-resistant leukemia with ginsenoside F1, Rg3 or their pharmaceutically acceptable salts exhibiting preventive or therapeutic effects as an active ingredient, including administering the pharmaceutical composition A method for treating Gleevec-resistant leukemia and a food composition for preventing or improving Gleevec-resistant leukemia. Background technique [0002] Methods mainly used in cancer treatment include surgery, anticancer chemotherapy, radiation therapy, and the like. Among them, surgery and radiation therapy are local therapies that are effective only on resected sites or irradiated sites, and ant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K45/06A61K31/506A61P35/02A23L33/10
CPCA23L33/10A23V2002/00A61K31/506A61K31/704A61K45/06A61K2300/00A23V2200/308A61P35/00A61P35/02A61K31/70A23L33/125
Inventor 金善昌金宪湜
Owner INTELLIGENT SYNTHETIC BIOLOGY CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com